The Vaccines are Coming!

DISCLAIMER

The information presented today is based on CDC's recent guidance and MAY change.

December 08, 2020

Discussion Topics

- Welcome and Opening Remarks
- COVID-19 Vaccine Updates
- Expert Vaccine Allocation Panel
- COVID-19 Texas Vaccine Allocation & Shipment
- COVID-19 Vaccine Storage, Handling & Administration
- COVID-19 Vaccine Safety Monitoring & Reporting
- Q&A

Welcome & Opening Remarks

Imelda Garcia, MPH

Associate Commissioner, Laboratory & Infectious Disease Services Division


COVID-19 Vaccine Allocations - Week 1
FOR PLANNING PURPOSES ONLY
Amarillo
Fort Worth
Dallas
Tyler
Midland
Odessa
El Paso
Waco
Austin
Houston
San Antonio
Corpus Christi
Laredo
Brownsville
COVID-19 Vaccine Storage Type
Ultra-cold Capacity (n=51)
Dry Ice Needed (n=59)
Public Health Region
As of December 7,2020
TEXAS
Health and Human Services
Texas Department of State Health Services

COVID-19 Vaccine Updates

Saroj Rai, PhD, MPH

COVID-19 Vaccine Updates

Phase III Vaccine Candidates	Technology Platform	Storage & Handling	Dose (Intramuscular Injection)
Pfizer	m-RNA	Ultra-low frozen: 6mos Refrigerated: 5 days	2 (0, 21 days)
moderna	m-RNA	Frozen: 6mos Refrigerated: 30 days	2 (0, 28 days)
AstraZeneca / University of Oxford	Viral Vector (Non-Replicating)	Refrigerated: 6mos	2 (0, 28 days)
janssen	Viral Vector (Non-Replicating)	Refrigerated: 6mos	1

Phase III Vaccine Candidates	Technology Platform	Efficacy & Safety			Regulatory Status
		Study Design	Interim Analysis	Completion of Primary Endpoint	
Pfizer	m-RNA	• N=44,000 • ≥ 12 yrs • Randomization (1:1) • Placebo vs. Vaccine • (Saline vs. 30 µg) • 2 doses (0, 21 days)	• 90% effectiveness (94 cases)	• **95%** vaccine efficacy (162 placebo vs. 8 vaccine) - 30 severe case (30 placebo vs. 0 vaccine) • Consistent efficacy across age, gender, race/ethnicity • No serious adverse reported to date	**EUA Filed**
moderna	m-RNA	• N=30,000 • ≥ 18 yrs • Randomization (1:1) • Placebo vs. Vaccine • (Saline vs. 100 µg) • 2 doses (0, 28 days)	• **94.5%** vaccine efficacy (90 placebo vs. 5 vaccine) - 11 severe case (11 placebo vs. 0 vaccine) - 16% adults ages >65 yrs - 21% diverse population • No serious adverse reported to date Grade 3 (>2%): Fatigue, myalgia, arthralgia, headache, pain, & redness at injection site	• **94.1%** vaccine efficacy (185 cases in placebo vs. 11 vaccine) - 11 severe case (11 placebo vs. 0 vaccine) - 17% adults ages >65 yrs - 21% diverse population • 1 death in the placebo group	**EUA Filed**
AstraZeneca / OXFORD	Viral Vector (Non-Replicating)	**UK Study** • N=12,390 • ≥ 18 yrs • 1 Dose vs. 2 Doses vs. MenACWY **Brazil Study** • N=10,300 • ≥ 18 yrs • 2 does vaccine vs. MenACWY/Saline	• **90%** vaccine efficacy (half dose/full dose ($5x10^{10}$ vp) with n=2,741 • **62%** vaccine efficacy (full dose/full dose (n=8,895) • Combined efficacy of **70% (131 COVID-19 cases)** • No serious adverse events have been reported thus far		
janssen	Viral Vector (Non-Replicating)	• N=60,000 • ≥ 18 yrs • Randomization (1:1) • Placebo vs. Vaccine (Saline vs. $5×10^{10}$ vp) • 1 doses			

Path to Vaccination

PFIZER

Dec. 10 → Dec. 11-14 → Dec. 11-14 → Dec. 14 -18

Begin Vaccination

VRBPAC Open Session Meeting

FDA Reviews all the Data → EUA → CDC ACIP Calls an Immediate Meeting → Recommendations

BLA (Biologics Licensure Application)
EUA (Emergency Use Authorization)
EA (Expanded Access)

MODERNA

Dec. 17 → Dec. 18-21 → Dec. 18-21 → Dec. 21-23

VRBPAC Open Session Meeting

FDA Reviews all the Data → EUA → CDC ACIP Calls an Immediate Meeting → Recommendations

Vaccination

BLA (Biologics Licensure Application)
EUA (Emergency Use Authorization)
EA (Expanded Access)

Expert Vaccine Allocation Panel (EVAP)

Imelda Garcia, MPH

Associate Commissioner, Laboratory & Infectious Disease Services Division

COVID-19 Expert Vaccination Allocation Panel (EVAP)

- Texas has convened a team of appointed external and internal subject-matter experts (SME) into the COVID-19 Expert Vaccine Allocation Panel (EVAP) to develop vaccine allocation strategies as recommendations to the Texas Commissioner of Health.
- The panel will develop and apply guiding principles in their recommendations.
- The recommendations from the EVAP will be sent to the Texas Commissioner of Health for final approval.
- EVAP voting members https://www.dshs.texas.gov/coronavirus/immunize/evap.aspx

TEXAS Health and Human Services

Texas Department of State Health Services

Texas Guiding Principles

- **Protecting health care workers** who fill a critical role in caring for and preserving the lives of COVID-19 patients and maintaining the health care infrastructure for all who need it.
- **Protecting front-line workers** who are at greater risk of contracting COVID-19 due to the nature of their work providing critical services and preserving the economy.
- **Protecting vulnerable populations** who are at greater risk of severe disease and death if they contract COVID-19.
- **Mitigating heath inequities** due to factors such as demographics, poverty, insurance status and geography.
- **Data-driven allocations** using the best available scientific evidence and epidemiology at the time, allowing for flexibility for local conditions.
- **Geographic diversity** through a balanced approach that considers access in urban and rural communities and in affected ZIP codes.
- **Transparency** through sharing allocations with the public and seeking public feedback.

https://gov.texas.gov/news/post/governor-abbott-dshs-announce-covid-19-vaccine-distribution-plan

COVID-19 Critical Population Update

Phase 1A Healthcare Workers Definition – First Tier

1. Hospital staff working directly with patients who are positive or at high risk for COVID-19. Includes:
    a. Physicians, nurses, respiratory therapists and other support staff (custodial staff, etc.)
    b. Additional clinical staff providing supporting laboratory, pharmacy, diagnostic and/or rehabilitation services
2. Long-term care staff working directly with vulnerable residents. Includes:
    a. Direct care providers at nursing homes, assisted living facilities, and state supported living centers
    b. Physicians, nurses, personal care assistants, custodial, food service staff
3. EMS providers who engage in 9-1-1 emergency services like pre-hospital care and transport
4. Home health care workers, including hospice care, who directly interface with vulnerable and high-risk patients
5. Residents of long-term care facilities

TEXAS Health and Human Services

Texas Department of State Health Services

COVID-19 Critical Population Update

Phase 1A Healthcare Workers Definition – Second Tier

1. Staff in outpatient care offices who interact with symptomatic patients. Includes:
    a. Physicians, nurses, respiratory therapists and other support staff (custodial staff, etc.).
    b. Clinical staff providing diagnostic, laboratory, and/or rehabilitation services
    c. Non 9-1-1 transportation for routine care
2. Direct care staff in freestanding emergency medical care facilities and urgent care clinics.
3. Community pharmacy staff who may provide direct services to clients, including vaccination or testing for individuals who may have COVID.
4. Public health and emergency response staff directly involved in administration of COVID testing and vaccinations.
5. Last responders who provide mortuary or death services to decedents with COVID-19. Includes:
    - Embalmers and funeral home workers who have direct contact with decedents
    - Medical examiners and other medical certifiers who have direct contact with decedents.
6. School nurses who provide health care to students and teachers.

COVID-19 Texas Vaccine Allocation Process

Joshua Hutchison, Vaccine Data and Finance Manager


Vaccine Allocation & Ordering System (VAOS)

Overview

As a COVID-19 Vaccine Provider, you will use the **Vaccine Allocation & Ordering System (VAOS)** and **Vaccine Management Dashboard** to perform tasks related to COVID-19 vaccine management.

In **VAOS,** you will be able to acknowledge vaccine allocations, confirm received shipments, view distribution information, and report waste.



The **Vaccine Management Dashboard** is accessed through VAOS and allows you to monitor your vaccine allocations, distribution supply, and administration metrics.

Understanding your Provider Actions in VAOS

As a Provider, you have **four primary functions in VAOS**:

1

ACCESSING DASHBOARDS

Useful for seeing your allocations, distribution supply, and administration metrics

2

ACKNOWLEDGING ALLOCATIONS

Required for your allocated vaccine doses to be submitted into the CDC ordering system

3

CONFIRMING SHIPMENTS

Required once you receive your vaccine doses

4

REPORTING WASTE

Required to track how many doses are unused/wasted

Key Vaccine Management Actions for Providers



Pfizer Vaccine Candidate
Shipment

Pfizer Vaccine Candidate Distribution & Shipment



Direct Shipment to Points of Vaccination

Direct Shipments* to Vaccination Center by Transport Courier

Pfizer has designed a distribution model which is built on a flexible just in time system to ship the vaccine from manufacturing site and/or storage facility directly to the points of vaccination.

Temperature & Location Tracking During Transportation



Controlant Reusable RTM Logger



- Each thermal shipper has reusable GPS enabled temperature monitoring device which will be enabled when the shipper is packed.
- All shipments will be tracked via the onboard GPS monitoring device to ensure end-to-end distribution within required temperatures.
- Shipments will be executed under the management of Pfizer Quality processes and controls to ensure that upon ownership transfer, product has arrived under acceptable conditions.
- Temperature records of the shipments can be shared with upon request.

*COVID Vaccine supply chain model is a drop ship direct from Pfizer manufacturing sites to the designated locations by the government.
Markets with no Pfizer commercial legal entity: Product ownership transfer at port of entry for governmental customer importation and in-market distribution

Current as of December 2020, Operation Warp Speed has requested that prior to the potential FDA authorization of the Pfizer-BioNTech Covid-19 Vaccine, Pfizer send select training materials containing information for properly storing, preparing and administering the vaccine to anticipated vaccination sites. Although there is no guarantee that the vacci will be authorized by FDA, given the urgency of the pandemic, providing these materials in advance will enhance sites' preparation. Materials, specifications and assumptions are subject to change. For the most up-to-date materials upon authorization, please visit www.cvdvaccine.com. Pfizer will not begin shipment of the vaccine unless and until FDA has

Vaccine Shipment – Provider Emails

Once the EUA has been issued and the vaccine is ready for distribution, you will receive shipment information and tracking numbers from the vendors. Please ensure that you are able to receive e-mails from the following addresses:

cvgovernment@pfizer.com	Pfizer Customer Service
Pfizer.logistics@controlant.com	For communication from Controlant, including: • Notice at time of vaccine shipment with tracking information • Exceptions for either shipment delay or cancellation • Delivery Quality Report
SNSSupport@McKesson.com	For communication from McKesson about ancillary kits

Please note, for the first shipment, you will receive ancillary supplies between Dec 9-11, prior to the arrival of the vaccine.

COVID-19 Texas Vaccine Allocation Summary

- Weekly allocation
- No need to hold back vaccine for the 2nd dose
- Please report doses administered into ImmTrac2 within 24 hours
- Please ensure all contact information is correct in the provider portal
- Ensure able to receive emails from the specific email addresses

TEXAS Health and Human Services

Texas Department of State Health Services

Pfizer Vaccine Candidate
Storage, Handling and Administration

Saroj Rai, PhD, MPH

Overview of Shipping, Storage & Handling

1 → 2 → 3

Thermal Shipper Arrival

The thermal shipper that the vaccine arrives in can be used as temporary storage, so long as dry ice is replenished upon receipt and every 5 days (up to 30 days).

The thermal shipper maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage within this temperature range is not considered an excursion from the recommended storage condition.

Storage & Handling

Storage options for vials/trays include:

1. **Ultra Low Temperature Freezer at** -80° and -60°C (-112 to -76°F) for up to 6 months
2. **Thermal Shipper at** -90°C to -60°C (-130°F to -76°F) for up to 30 days from delivery, if replenished with dry ice upon receipt and every 5 days
3. **Refrigerator** at 2 to 8 °C (35.6° to 46.4°F) for up to 120 hours (5 days)

Vial are glass and should be handled with care. Visual inspection prior to use should be carried out.

Vials should be protected from light and kept in the original packaging.

Vials should always remain upright in trays during storage.

Returning Thermal Shipper

The thermal shipping container may be used as temporary storage for up to 30 days from delivery, including temperature data logger.

Current as of December 2020, Operation Warp Speed has requested that prior to the potential FDA authorization of the Pfizer-BioNTech Covid-19 Vaccine, Pfizer send select training materials containing information for properly storing, preparing and administering the vaccine to anticipated vaccination sites. Although there is no guarantee that the vaccine will be authorized by FDA, given the urgency of the pandemic, providing these materials in advance will enhance sites' preparation. Materials, specifications and assumptions are subject to change. For the most up-to-date materials upon authorization, please visit www.cvdvaccine.com. Pfizer will not begin shipment of the vaccine unless and until FDA has

Ultra Low Temperature Thermal Shipper – Overview of Pack Out



ITEM	DESCRIPTION
1	VIP LID
2	DRY ICE POD
3	PAYLOAD SLEEVE (Takes 1 to 5 vial trays)
4	MEDIUM ULT THERMAL SHIPPER

Softbox Medium ULT Weights and Dimension	
Empty Shipper Weight	8.5 kgs
Available Payload Space	9.65" x 9.65" x 9.49"
External Dimension	15.75" x 15.75" x 22.04"
Amount of Dry Ice	23 kgs
Tare Weight w/ Dry Ice	31.5 kgs
Total Weight w/ 1 Vial Tray	32.6 kgs
Total Weight w/ 5 Vial Trays	36.7 kgs

Weight of Vial Tray	1.038 kgs

Ultra-Low Temperature Freezer (ULTF)

Temperature

- Store as frozen liquid at -80ºC to -60 ºC (-112°F to -76°F) for long term storage up to 6 months.
- Different size of ULT freezers are may be available for purchase by points of vaccination
- **A small size (under or over the countertop ULT Freezers can store as much as 30K doses).**

Illustrative Only

Product Transfer from Thermal Shipper to ULTF



1

Remove Dry Ice Pod from shipper

2

Remove the Payload Box from the thermal shipper by carefully pulling directly upwards with the handles.

Immediately store vial trays in an ultra-low temperature (ULT) freezer. Do not open the vial trays until you are ready to remove vials for thawing or use.

3

Monitor freezer temperatures

*Product temperature must always be monitored to ensure adherence to temperature requirements for different storage conditions are being met in alignment with site Standard Operating Procedures.

Please note that it is possible that the final preparation and logistical requirements may change in light of forthcoming data on dosing, stability, manufacturing and shipping requirements, but this deck reflects the Company's current understanding based on the totality of available data currently. Current as of September 8, 2020.

Product Packaging Overview

Vials

2 mL Type 1 glass preservative-free

- 2 mL type 1 glass preservative free multi-dose vial (MDV)
- MDV has 0.45 mL frozen liquid drug product
- 5 doses per vial after dilution

Trays

- Single tray holds 195 vials
- 975 doses per tray
- A smaller tray, containing 25 vials (125 doses) is in development with estimated availability in early 2021

Thermal Shipper



- Minimum 1 tray (975 doses) or up to 5 trays (4875 doses) stacked in a payload area of the shipper
- Payload carton submerged in dry ice pellets
- Thermal shipper keeps ULT -90ºC to -60ºC (-130ºF to -76ºF) up to 10 days if stored at 15°C to 25°C (5° to 77°F) temperatures without opening
- Thermal shippers are reusable and designed to be a temporary storage containers by replenishing dry ice.

Current as of December 2020, Operation Warp Speed has requested that prior to the potential FDA authorization of the Pfizer-BioNTech Covid-19 Vaccine, Pfizer send select training materials containing information for properly storing, preparing and administering the vaccine to anticipated vaccination sites. Although there is no guarantee that the vac will be authorized by FDA, given the urgency of the pandemic, providing these materials in advance will enhance sites' preparation. Materials, specifications and assumptions are subject to change. For the most up-to-date materials upon authorization, please visit www.cvdvaccine.com. Pfizer will not begin shipment of the vaccine unless and until FDA has

Key Timing Considerations

TRAYS

3 MINS

Open-lid vial trays, or vials trays containing less than 195 vials removed from frozen storage (< -60°C) may be at room temperature (< 25°C) for up to **3 minutes** for transfer between ultra low temperature environments or to remove vials for thawing or use.

5 MINS

Closed-lid vial trays containing 195 vials removed from frozen storage (< -60°C) may be at room temperature (< 25°C) for up to **5 minutes** for transfer between ultra low temperature environments.

2 HRS

After vial trays are returned to frozen storage following room temperature exposure, they must remain in frozen storage for at least **2 hours** before they can be removed again.

VIALS

Once an individual vial is removed from a vial tray at room temperature, it should not be returned to frozen storage and should be thawed for use.

Cold Storage Comparison

Cold Storage Limitations	ULTF (up to 6 months)	Thermal (up to 30 Days)	Fridge (up to 5 Days)
Availability of Full-time Immunizers	No Restriction	Minimum 2 Immunizers	Minimum 4 Immunizers
Anticipated Patient Flow	Minimum 960 patients in 6 months	Minimum 960 patients in 30 days	Minimum 960 patients in 5 days
Allows for Variability in Patient Flow (e.g. walk-ins)	Yes	No	No
Requires Dry Ice Ordering/ Handling	No	Yes	No

Refrigerator Usage

Product Refrigeration

Product can be stored at 2 to 8 °C (35.6° to 46.4°F) refrigerator up to 120 hours (5 days).

Product Thawing

Based on current stability studies, a tray of 25 vials or 195 vials may take up to 2 or 3 hours to thaw in the refrigerator, respectively, whereas a fewer number of vials will thaw in less time.

Either: Transfer the frozen vials immediately to a refrigerator at 2 to 8 °C (35.6° to 46.4°F).

Or: Vials needed for immediate use can be thawed at room temperature (30 minutes); room temperature hold time is no more than 2 hours.

Vials thawed at room temperature form condensation on the outside of the vial, so thawing in a secondary container is recommended.

Vials may be stored in the refrigerator prior to dilution for up to 5 days (120 hours).

Vials may be held at room temperature for no more than 2 hours prior to dilution.

Re-icing Thermal Shipper

Handling instructions

- Re-ice at a minimum of every 5 days (based on normal use). No restriction to number of re-icing. If box is left open for longer than 3 minutes, recommendation is to re-ice more frequently, as needed.
- If re-icing occurs and a holiday or weekend, plan ahead to re-ice the thermal shipping container.
- Thermal shipping container may be used as temporary storage for up to 30 days from delivery.
- Sites are required to maintain temperature monitoring.

3 MINS

Thermal Shipper opening:
twice daily, max 3 minutes each

M Tu W Th F Sa Su M Tu W Th F Sa Su M Tu W Th F Sa Su M Tu W Th F Sa Su M Tu W Th

Shipper arrives with 80% energy

Upon receipt and after opening, the box should be replenished/inspected with dry ice within 24 hours

Re-ice shipper

Re-ice shipper

Re-ice shipper

Re-ice shipper

Re-ice shipper

Return shipper

SHIPPER ENERGY LEVEL

Vaccine Preparation and Administration

Point Of Use (POU)

Removing the Vials to Thaw

From storage, **remove 1 vial for every 5 recipients** according to planned vaccinations schedule.

Vials may be stored in the refrigerator for 5 days (120 hours).

Dilute the Vaccine

Obtain 0.9% Sodium Chloride Injection, USP for use as a diluent
Do not use any alternate diluents.

Dilute the thawed vial by adding **1.8 mL of 0.9% Sodium Chloride Injection** into the vial.

Ensure vial pressure is equalized by **withdrawing 1.8 mL air** into the empty diluent syringe before removing the needle from the vial.

Preparing the Dose



Draw up 0.3 mL of the diluted dosing solution into a new sterile dosing syringe with a needle appropriate for intramuscular injection.

For each additional dose, use a new sterile syringe and needle and ensure the vial stopper is cleansed with antiseptic before each withdrawal.

Vaccine Administration



Pfizer BioNTech COVID-19 Vaccine 30 mcg/0.3 mL

Diluted vials must be used within 6 hours from the time of dilution and stored between 2°C to 25°C (35°F to 77°F).

A single 30 mcg/0.3 mL dose followed by a second dose 21 days later.

21 DAYS

Vaccine Preparation Instruction

Point Of Use (POU)

Supplies Required to Prepare:

- 1 Vial Pfizer BioNTech COVID-19 Vaccine

- 1 Vial 0.9% Sodium Chloride Injection (at least 2 mL)
- 1 diluent syringe/needle (3 mL or 5mL syringe/21 G needle recommended)
- 5 dosing syringes/needles (1 mL syringe/ IM injection needle)
- Other ancillary materials such as alcohol swabs, gloves, PPE



COVID-19 Vaccine Safety Monitoring

COVID-19 Vaccine Safety Monitoring

Monitoring Plan	Type	Lead Federal Agency	Collaborating Agencies and Partners
Vaccine Adverse Event Reporting System (VAERS)	Passive	CDC	FDA
Biologics Effectiveness and Safety (BEST) System	Active	FDA	Several Health Plans, Academia, IBM Watson
FDA-Center for Medicare & Medicaid Services (CMS) Partnership	Active	FDA	CMS
FDA and other Government Entities Partnership	Active / Passive	FDA	CDC, CMS, VA, NIH, DOD & IHS
Vaccine Effectiveness Surveillance Plans	Passive	FDA	CDC
Vaccine Safety Datalink (VSD)	Passive	CDC	9 Health Plans
Clinical Immunization Safety Assessment (CISA) Project	Active	CDC	7 Medical Research Centers
V-safe	Active	CDC	FDA

CDC + FDA

VAERS

Vaccine Adverse Event Reporting System

Co-managed by CDC and FDA

http://vaers.hhs.gov



VAERS is the nation's frontline system for monitoring vaccine safety

YouTube

Search

https://www.youtube.com/watch?v=sbCWhcQADFE

New Vaccine Adverse Event Reporting System (VAERS) Website and Ways to Report

v-safe | *after vaccination health checker*

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide **personalized health check-ins** after someone receives a COVID-19 vaccination.

Vaccine recipients can quickly tell the CDC if they have any side effects. The CDC may follow up with them by phone to get more information.

V-safe will also remind them to get their second COVID-19 vaccine dose, if needed.

v-safe℠
after vaccination health checker



v-safe | *after vaccination health checker*

How long do v-safe check-ins last?

- During the first week after you get your vaccine, ***v-safe*** will send you a text message each day to ask how you are doing.
- Then you will get check-in messages once a week for up to 5 weeks.
- The questions ***v-safe*** asks should take less than 5 minutes to answer.
- If you need a second dose of vaccine, ***v-safe*** will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well.
- You'll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.

v-safe℠
after vaccination health checker



v-safe | *your role as a provider*

- Give patients a **v-safe** information sheet at the time of vaccination
- Encourage them to enroll and fill out the surveys when prompted

https://vsafe.cdc.gov/

v-safe info poster

v-safe info sheets

Resources

- COVID-19 Vaccine Provider Registration Information: www.dshs.texas.gov/coronavirus/immunize/provider-information.aspx
- FAQ for Providers https://www.dshs.texas.gov/immunize/covid19/COVIDproviderfaq.pdf
- DSHS COVID-19 Vaccine Provider hotline:
- (877) 835-7750, 8 a.m. to 5 p.m., Monday through Friday or Email: COVID19VacEnroll@dshs.texas.gov
- Website to enroll as a COVID-19 Vaccine Provider: EnrollTexasIZ.dshs.texas.gov

TEXAS Health and Human Services

Texas Department of State Health Services

DISCLAIMER

The information presented today is based on CDC's recent guidance and MAY change.

December 08, 2020